References
- Mayer EA. Irritable bowel syndrome. N. Engl. J. Med.358, 1692–1699 (2008).
- Drossman DA. Rome III: The Functional Gastrointestinal Disorders. Degnon Associates Inc., VA, USA (2006).
- Mangel AW, Northcutt AR. Review article: the safety and efficacy of alosetron, a 5HT3 receptor antagonists, in female irritable bowel syndrome patients. Aliment. Pharmacol. Ther.13(Suppl. 2), 77–82 (1999).
- Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment. Pharmacol. Ther.13, 1149–1159 (1999).
- Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial. Lancet.355, 1035–1040 (2000).
- Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F. Tegaserod, a 5-HT4 receptor agonist, relieves symptoms on irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther.15, 1655–1666 (2001).
- Drossman DA, Chey WD, Johanson JF et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment. Pharmacol. Ther.29, 329–341 (2009).
- Mangel AW, Fehnel SE. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists. Neurogastroenterol. Motil.20, 1086–1093 (2008).
- Mangel AW, Hahn BA, Heath AT et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J. Int. Med. Res.26, 76–81 (1998).
- Mangel AW. Study design issues in irritable bowel syndrome. Aliment. Pharmacol. Ther.19, 141–142 (2004).
- Mangel AW. Personal view: adequate relief as a primary endpoint in irritable bowel syndrome. Aliment. Pharmacol. Ther.23, 879–881 (2006).
- Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin. Gastroenterol. Hepatol.5, 534–540 (2007).
- Mangel AW. The FDA and IBS drug development. Am. J. Gastroenterol.104, 3106 (2009).
- Mangel AW, Wang J, Sherrill E, Gnanasakthy A, Ervin C, Fehnel SE. Urgency as an endpoint in irritable bowel syndrome. Gastroenterol. Res.4, 9–12 (2011).
Websites
- US Department of Health and Human Services, FDA. Guidance for industry – irritable bowel syndrome: clinical evaluation of products for treatment. March 2010 www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM205269.pdf (Accessed 1 April 2010)
- US Department of Health and Human Services, FDA. Guidance for industry – patient-reported outcome measures: use in medical product development to support labeling claims. December 2009 www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (Accessed 10 December 2009)